Because of the ensuing pancytopenia from systemic chemotherapy including lymphopenia, we elected to explore the combination of radiotherapy with C3a/C3aR axis inhibition to enhance NK cell–based immunotherapy against pancreatic cancer. This evidence concerns the gene C3AR1 and lymphopenia.